Aurora Cannabis (ACB) Total Non-Current Liabilities (2018 - 2025)
Aurora Cannabis (ACB) posted quarterly Total Non-Current Liabilities of $44.1 million for Q4 2025, down 57.7% year-over-year from $104.3 million in Q4 2024, and down 7.5% quarter-over-quarter from $47.7 million in Q3 2025.
Aurora Cannabis (ACB) Total Non-Current Liabilities (2018 - 2025) Analysis & Trends
Aurora Cannabis (ACB) has reported Total Non-Current Liabilities for 8 consecutive years, with $44.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 57.7% year-over-year to $44.1 million; the TTM figure through Dec 2025 stood at $44.1 million (down 57.7% YoY), while the FY2025 annual figure was $95.8 million, down 14.58% from the prior year.
- Total Non-Current Liabilities slipped to $44.1 million in Q4 2025 per ACB's latest filing, from $47.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $438.0 million in Q3 2022 and bottomed at -$4.2 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $194.8 million across 5 years, with a median of $151.5 million in 2023.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities slumped 185.49% — and 2023, when it surged 3688.19%.
- Aurora Cannabis' Total Non-Current Liabilities stood at $419.1 million in 2021, then dropped by 25.22% to $313.4 million in 2022, then sank by 51.62% to $151.6 million in 2023, then slumped by 31.19% to $104.3 million in 2024, then tumbled by 57.7% to $44.1 million in 2025.
- Business Quant data shows ACB's Total Non-Current Liabilities at $44.1 million in Q4 2025, $47.7 million in Q3 2025, and $66.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Aurora Cannabis | 232.22 Mn | 159.91 Mn | 25.75 Mn | 67.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 44.12 Mn |
| Sep 30, 2025 | 47.70 Mn |
| Jun 30, 2025 | 66.59 Mn |
| Mar 31, 2025 | 92.84 Mn |
| Dec 31, 2024 | 104.32 Mn |
| Sep 30, 2024 | 116.71 Mn |
| Jun 30, 2024 | 119.54 Mn |
| Mar 31, 2024 | 171.57 Mn |
| Dec 31, 2023 | 151.60 Mn |
| Sep 30, 2023 | 151.35 Mn |
| Jun 30, 2023 | 152.26 Mn |
| Mar 31, 2023 | 296.00 Mn |
| Dec 31, 2022 | 313.37 Mn |
| Sep 30, 2022 | 438.02 Mn |
| Jun 30, 2022 | -4.24 Mn |
| Mar 31, 2022 | 378.58 Mn |
| Dec 31, 2021 | 419.08 Mn |
| Sep 30, 2021 | 422.99 Mn |
| Jun 30, 2021 | -1.49 Mn |
| Mar 31, 2021 | 415.25 Mn |